{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:46:54Z","timestamp":1792010814738,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007482","name":"Arizona State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007482","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030840","name":"Iovance Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009230","name":"Norris Cotton Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100009230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.044","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:31:10Z","timestamp":1777876270000},"page":"1098-1110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Lilit","family":"Karapetyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara T.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Otteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie K.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Smithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Nayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Tawashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amritha","family":"Seshaadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich Graf","family":"Finckenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.04.044_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2020.09.003","article-title":"State of melanoma: an historic overview of a field in transition","volume":"35","author":"Karapetyan","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2026.04.044_bib0002","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.04.044_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.044_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.044_bib0005","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0006","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMc2119768","article-title":"CTLA-4 blockade resistance after relatlimab and nivolumab","volume":"386","author":"Menzies","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.044_bib0007","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0008","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2026.04.044_bib0010","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0011","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0012","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.044_bib0013","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2026.04.044_bib0014","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2026.04.044_bib0015","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0016","doi-asserted-by":"crossref","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.04.044_bib0017","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0018","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PPO.0000000000000608","article-title":"Surgical considerations for tumor tissue procurement to obtain tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"28","author":"Mullinax","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.jtct.2026.04.044_bib0019","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jtct.2026.04.044_bib0020","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.04.044_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0022","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.044_bib0023","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.jtct.2024.11.013","article-title":"The clinical TIL experience in melanoma: past, present, future","volume":"31","author":"Smithy","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.04.044_bib0024","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1016\/j.jtct.2024.11.017","article-title":"Tumor-infiltrating lymphocyte therapy for melanoma and other solid tumors: looking back, yet moving forward","volume":"31","author":"Shoushtari","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.04.044_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1245\/s10434-017-6266-8","article-title":"Metastasectomy for tumor-infiltrating lymphocytes: an emerging operative indication in surgical oncology","volume":"25","author":"Crompton","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.12.009","article-title":"Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patients","volume":"32","author":"Karapetyan","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.04.044_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.04.044_bib0028","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/14796694.2025.2498842","article-title":"Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma","volume":"21","author":"Mushtaq","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtct.2026.04.044_bib0029","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.jtct.2025.12.248","article-title":"Real world outcomes of a single-center tumor infiltrating lymphocyte (TIL) melanoma therapy program with commercial lifileucel","volume":"32","author":"Desai","year":"2026","journal-title":"Transplant Cell Ther"}],"updated-by":[{"DOI":"10.1016\/j.jtct.2026.09.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000}}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:52:00Z","timestamp":1788987120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003295"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.044","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}